Last updated: February 14, 2026
Product Overview
NDC 00115-5211 refers to Hyperacidity Ulcer Therapy Tablets—specifically, a brand of famotidine. Famotidine, marketed primarily as Pepcid, is an H2 receptor antagonist used to treat gastroesophageal reflux disease (GERD), ulcers, and Zollinger-Ellison syndrome. The drug is available in both prescription and over-the-counter (OTC) formulations in the United States.
Market Landscape
Market Size and Adoption
- The global H2 receptor antagonist market was valued at approximately $1.5 billion in 2022, with famotidine representing roughly 65% of this market in the U.S. (source: IQVIA).
- In the U.S., famotidine sales total approximately $400 million annually, driven by OTC availability and prescription use.
- The shift toward OTC formulations has increased consumer access, influencing annual market growth rates between 3% and 5%.
Key Competitors
- Esomeprazole (Nexium)
- Omeprazole (Prilosec)
- Ranitidine (withdrawn in some markets due to safety concerns)
- Other OTC antacids like calcium carbonate or magnesium hydroxide
Regulatory Environment
- The drug's OTC approval in 2015 expanded its reach, reducing prescription reliance.
- FDA safety alerts in 2020 concerning ranitidine’s carcinogenic risks increased famotidine’s market share as a preferred alternative.
Pricing Landscape
Historical Price Trends
- Prescription famotidine typically sells for approximately $5–$20 per bottle of 30 tablets (varies by pharmacy and insurance coverage).
- OTC formulations are priced around $8–$15 per package, depending on size and retailer.
- Generic famotidine prices are substantially lower than branded equivalents, with some discount programs reducing consumer costs further.
Current Pricing (as of 2023)
| Formulation |
Typical Retail Price |
Insurance Coverage |
Cost to Consumer (after insurance) |
| Prescription (30 tablets 20 mg) |
$8–$20 |
Variable |
$2–$5 |
| OTC (60 tablets 10 mg) |
$8–$15 |
Not covered |
$8–$15 |
Pricing Projected Trends
- As patents for branded products have expired, generic famotidine will continue to dominate the market.
- Price erosion for generics is likely to persist at a rate of 2–4% annually due to increased competition.
- Hospital and specialty segments may see higher prices ($15–$30 per course) due to formulary restrictions and compounding.
Market Drivers and Constraints
Drivers
- Increased OTC availability
- Growth of chronic GERD and ulcer conditions
- Safety profile favorable compared to PPIs in some patient groups
- Escalating demand due to anti-ranitidine safety concerns
Constraints
- Competition from PPI medications, which are often more potent
- Concerns about long-term efficacy and safety
- Pricing pressures from pharmacy benefit managers (PBMs) and insurers
- Potential regulatory changes affecting OTC status or safety labeling
Future Outlook and Projections
- The famotidine market in the U.S. is expected to grow at a compound annual growth rate (CAGR) of approximately 3% over the next five years, reaching about $500 million in annual sales by 2028.
- Price stabilization for generics will persist, with minor declines due to market saturation.
- Introduction of combination products or targeted formulations could diversify product offerings, impacting pricing dynamics.
Investment and Business Implications
- Opportunities exist for companies to expand OTC marketing and bundle famotidine with other gastrointestinal medications.
- Price competition will likely focus on optimizing supply chain efficiencies and minimizing manufacturing costs.
- Patent challenges or formulations with improved efficacy could alter the competitive landscape.
Key Takeaways
- NDC 00115-5211, as famotidine, has a stabilized market with steady growth driven by OTC availability.
- The market's value remains around $400–$500 million annually in the U.S.
- Pricing trends indicate continued generic price erosion, with retail prices remaining low relative to branded versions.
- Growth opportunities reside in expanding OTC sales, especially in markets with safety concerns over PPIs.
- Market consolidation and regulatory actions may influence future price and market share dynamics.
FAQs
Q1: How does the current market size for famotidine compare globally?
Global sales approximate $1.5 billion, with the majority concentrated in North America and Europe.
Q2: What regulatory changes could impact famotidine pricing?
Any FDA decision to revoke OTC status or impose new safety labeling could reduce market penetration and influence pricing.
Q3: How does famotidine's safety profile compare to PPIs?
Famotidine generally has fewer long-term safety concerns, contributing to its preference in certain patient populations.
Q4: Are novel formulations or combination therapies expected to influence the market?
Yes. Developments in combination drugs or enhanced delivery systems could disrupt current pricing and market share.
Q5: What factors are likely to influence future price trends?
Competitive pressures, patent status, regulatory updates, and shifts in prescribing practices.
Citations
[1] IQVIA. U.S. Prescription Drug Market Report, 2022.
[2] FDA. Safety Alert on Ranitidine, 2020.
[3] MarketWatch. Gastrointestinal Drugs Market Forecast, 2023.
